undamentalytics Newsletter

Baker Bros. Advisors LP: insider trades

Director, 10% owner at 7 companies we cover. 13 open-market purchases and 1 sale not made under a pre-set plan, reported from June 5, 2013 to May 27, 2026.

Would copying Baker Bros. Advisors LP’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 13 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on June 6, 2013 into $6,009 by November 2, 2026, −3.7% a year. The copy held shares only 61% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $38,986, +10.7% a year (the S&P 500 held throughout made $58,423, +14.1% a year). Beta against the index was 0.60. Twelve months after each report, the average purchase was +11.6% against the S&P 500 (median +10.2%), and 54% beat it. Measured from the trade date, the insider’s own timing, the average was +20.5%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k$60.0k 2013201520172019202120232025 $58.4k$39.0k$6.0k
Copying Baker Bros. Advisors LPS&P 500, same days investedS&P 500, held throughout $10,000 copying Baker Bros. Advisors LP’s open-market purchases from June 6, 2013, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−3.7%
S&P 500, same days invested
+10.7% (held throughout +14.1%)
Time in shares
61%
Sharpe ratio (S&P 500)
0.25 (0.75)
Biggest drop (S&P 500)
−97% (−34%)
Market sensitivity (beta)
0.60
Purchases copied
13

Trade by trade

Baker Bros. Advisors LP: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 13 +15.9% −18.8% 46% 8 0.87 0.41 No reliable evidence
Purchases, 6 months after the report 13 +22.6% −0.8% 46% 8 0.66 0.53 No reliable evidence
Purchases, 12 months after the report 13 +11.6% +10.2% 54% 8 0.24 0.82 No reliable evidence
Purchases, 12 months after the trade 13 +20.5% +19.1% 62% 8 0.67 0.52 No reliable evidence
Sales, 3 months after the report 1 +25.7% +25.7% 0% 1 — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Neurogene Inc. NGNE —30January 20, 2016January 9, 2017
Beone Medicines Ltd. ONC —21August 14, 2017May 27, 2026
Kodiak Sciences Inc. KOD —30August 21, 2020January 31, 2022
Entrada Therapeutics, Inc. TRDA —20May 18, 2022May 24, 2022
Acadia Pharmaceuticals Inc ACAD —10June 5, 2013June 5, 2013
Incyte INCY —10September 8, 2017September 8, 2017
Madrigal Pharmaceuticals, Inc. MDGL —10December 14, 2023December 14, 2023

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 27, 2026May 22, 2026 ONC Sale $261,972 +25.7%not yetnot yet
December 14, 2023December 13, 2023 MDGL Purchase $22,516,773 +1.8%−0.9%+3.8%
May 24, 2022May 20, 2022 TRDA Purchase $282,409 +129.9%+80.1%+113.9%
May 18, 2022May 16, 2022 TRDA Purchase $430,778 +103.2%+104.5%+126.5%
January 31, 2022January 27, 2022 KOD Purchase $18,084,701 −82.0%−79.9%−79.4%
October 1, 2021September 30, 2021 KOD Purchase $8,330,694 −21.0%−81.3%−76.4%
August 21, 2020August 19, 2020 KOD Purchase $9,814,607 +163.1%+42.2%+55.5%
August 6, 2018August 2, 2018 ONC Purchase $627,922,800 −25.4%−30.5%−29.7%
September 8, 2017September 8, 2017 INCY Purchase $13,200,000 −29.8%−64.7%−66.2%
August 14, 2017August 11, 2017 ONC Purchase $12,499,976 +13.6%+108.9%+106.2%
January 9, 2017January 9, 2017 NGNE Purchase $6,837,122 −25.8%−59.3%−58.9%
March 16, 2016March 15, 2016 NGNE Purchase $3,771,920 −18.8%+82.0%+77.5%
January 20, 2016January 19, 2016 NGNE Purchase $1,774,214 −27.8%+38.8%+74.8%
June 5, 2013June 3, 2013 ACAD Purchase $33,560,731 +25.4%+10.2%+19.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Baker Bros. Advisors LP traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.